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baseline.8 They reported a higher incidence of acute kidney injury
(AKI) with TVR/BOC (N=34/193; 17.6%) than SOF containing regi-
mens (N=26/233; 11.2%). Not surprisingly, univariable logistic
regression analyses showed that decompensated cirrhosis, presence
of ascites, hypertension, and the use of NSAIDs and diuretics were
associated with AKI. The episodes of AKI in general were mild and
most resolved (N=51/59; 86.4%) with serum creatinine (SCr) return-
ing to baseline at the end of the follow-up approximately 12 weeks
after end of therapy. The majority of the patients in SOF group who
experienced AKI (N=17/26; 65%) were cirrhotics and 42% (N=11/
26) had decompensated cirrhosis. Three patients in SOF group
(1.3%) did not recover their renal function. Two of these patients
had impaired renal function at baseline (eGFR 37.9 and 55.1 mL/
min) while the other patient had a mild stage 1 AKI with SCr
increase of 0.3 mg/dL (26mcg/L) over the baseline.
Despite, its widespread use, sofosbuvir has not been reliably
linked to AKI. The study by Manns et al. is important as it exami-
nes the incidence of AKI in patients treated with sofosbuvir with
normal renal function and it is reassuring that AKI is an infrequent
complication. Although mild and mostly reversible, AKI episodes
were more frequent in patients with decompensated cirrhosis. It is
possible that AKI was a complication of advanced cirrhosis and
not necessarily caused by sofosbuvir. Regardless, this study re-
enforces that HCV therapy in patients with decompensated cirrho-
sis require careful monitoring and frequent assessment of renal
function.
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We thank Drs. Hussaini and Yoshida for their insightful comments
regarding our paper.1,2 Our research question derived from the clini-
cal observation of patients developing acute kidney injury (AKI) while
on direct-acting antiviral (DAA) regimens, followed by reversal of
kidney dysfunction when other potentially nephrotoxic drugs were
removed (eg diuretics, NSAID’s, ACE inhibitors). Although the
comparison of sofosbuvir (SOF)-based regimens with antivirals now
discontinued from the market (ie boceprevir [BOC] and telaprevir
[TPV]) is perhaps not ideal, our intention was to use BOC/TPV as a
reference, particularly since these regimens were linked to AKI in
postmarketing surveillance publications. Our results showed that
SOF-based regimens are less prone to causing AKI than BOC/TPV
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despite the fact that we treated sicker patients at high risk of renal
injury in the SOF era. We found very few cases of significant and
irreversible SOF-induced AKI and as Drs. Hussaini and Yoshida
clearly pointed out, when AKI occurred, it was most commonly
noted in patients with more advanced liver disease or having other
risk factors for nephrotoxicity. Our data suggest that although the
overall the risk of AKI with SOF-based therapy is low, kidney func-
tion monitoring remains important in patients with higher baseline
risk for AKI.
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